Haemonetics Reports 8% Revenue Growth for Third Quarter of Fiscal 2012 and $0.86 Adjusted EPS; Announces Multi-Year Contract Extensions With Key Plasma Collection Customers; And Affirms Fiscal 2012 Guidance